In January 2026, the Centers for Medicare & Medicaid Services (CMS) will implement a key provision of the Inflation Reduction Act, reimbursing select drugs at the Maximum Fair Price (MFP). This shift introduces a manufacturer rebate model, raising questions about its impact on pharmacy cash flow and interest costs.
Our latest white paper, authored by IQVIA Market Access Technology Solutions and leading experts, delivers a data-driven analysis of how the MFP rebate model will affect pharmacies, manufacturers, and patients. The study also compares these effects to the 340B Drug Pricing Program’s rebate pilot, offering actionable insights for stakeholders across the healthcare ecosystem.
Related solutions
Data, AI, and expertise empower Commercial Solutions to optimize strategy, accelerate market access, and maximize brand performance.
Grow your brand, now and through patent expiry
Gain high value access and increase the profitability of your brands